BriaCell

TSX:BCT

Developing Personalized Off-The-Shelf Immunotherapy Treatments for Cancer Patients

​Company Highlights

  • BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer.
  • BriaCell has partnered with Waisman Biomanufacturing to manufacture and supply prostate cancer immunotherapy
  • The company has entered a research agreement with Harvard Medical School in support of a project led by Joan S. Brugge to identify Novel targets for cancer treatment
  • BriaCell secured an exclusive license from the University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80) as a biologic agent for the treatment of cancer.
  • BriaCell signed an agreement with Caris Life Sciences to develop immunotherapies that are personalized for each patient by expanding patient outreach and molecular profiling.
  • BriaCell’s lead drug candidate Bria-IMT™ is targeting third-line advanced breast cancer with Phase I/IIa safety and efficacy showing similar or superior results to other advanced or approved drugs at a comparable stage
  • The company plans to initiate a registration study on Bria-IMT™ combined with an immune checkpoint inhibitor during the first quarter of 2023.
  • BriaCell’s clinical strategy team is involved in 19 drug approvals
  • Bria-OTS™, is currently being manufactured at a cGMP facility and undergoing quality control testing for the potential upcoming clinical trial for patients with advanced breast cancer.
  • BriaCell has received fast track status for Bria-IMT™ from the US Food and Drug Administration (FDA).
Press Releases


Overview

BriaCell Therapeutics (NASDAQ:BCTX, BCTXW;TSX:BCT) is a clinical-phase biotechnology company developing innovative immunotherapies for treating cancer.

At the forefront of cancer treatments, immunotherapies boost the ability of the body's own cancer-fighting cells to destroy cancerous tumors. Immunotherapies also have low-toxicity, making it easier for patients to undergo treatment. Most importantly, they may offer better efficacy and less chance of recurrence for many cancer patients. A report released by Research and Markets says the global immuno-oncology market is expected to reach US$135 billion by 2024. BriaCell continues to uncover opportunities in this space with its innovative technologies.

Company Highlights

  • BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer.
  • BriaCell has partnered with Waisman Biomanufacturing to manufacture and supply prostate cancer immunotherapy
  • The company has entered a research agreement with Harvard Medical School in support of a project led by Joan S. Brugge to identify Novel targets for cancer treatment
  • BriaCell secured an exclusive license from the University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80) as a biologic agent for the treatment of cancer.
  • BriaCell signed an agreement with Caris Life Sciences to develop immunotherapies that are personalized for each patient by expanding patient outreach and molecular profiling.
  • BriaCell’s lead drug candidate Bria-IMT™ is targeting third-line advanced breast cancer with Phase I/IIa safety and efficacy showing similar or superior results to other advanced or approved drugs at a comparable stage
  • The company plans to initiate a registration study on Bria-IMT™ combined with an immune checkpoint inhibitor during the first quarter of 2023.
  • BriaCell’s clinical strategy team is involved in 19 drug approvals
  • Bria-OTS™, is currently being manufactured at a cGMP facility and undergoing quality control testing for the potential upcoming clinical trial for patients with advanced breast cancer.
  • BriaCell has received fast track status for Bria-IMT™ from the US Food and Drug Administration (FDA).

The Conversation (0)
×